Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Mylotarg
|
| gptkbp:activities |
delivers cytotoxic agent to cancer cells
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2000
gptkb:2017 gptkb:FDA |
| gptkbp:clinical_trial |
Phase 3
improved overall survival monotherapy or in combination therapy increased remission rates |
| gptkbp:contraindication |
hypersensitivity to the drug
active liver disease |
| gptkbp:developed_by |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:dosage_form |
lyophilized powder for solution
|
| gptkbp:education |
avoid live vaccines during treatment
report any signs of infection stay hydrated during treatment follow-up appointments are crucial monitor for bleeding |
| gptkbp:formulation |
conjugated with calicheamicin
|
| gptkbp:frequency |
once every 14 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
gemtuzumab ozogamicin
|
| gptkbp:indication |
gptkb:relapsed_or_refractory_acute_myeloid_leukemia
|
| gptkbp:ingredients |
C6464 H10000 N1720 O2000 S40
|
| gptkbp:interacts_with |
live vaccines
other myelosuppressive agents |
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:is_used_for |
treatment of acute myeloid leukemia
|
| gptkbp:lifespan |
approximately 3 days
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
gptkb:Mylotarg
|
| gptkbp:pharmacokinetics |
gptkb:monoclonal_antibody
biphasic elimination |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:research_focus |
biomarker identification
long-term outcomes combination with other therapies |
| gptkbp:rounds |
primarily hepatic
|
| gptkbp:safety_features |
risk of infection
risk of liver toxicity risk of serious bleeding |
| gptkbp:side_effect |
thrombocytopenia
infusion-related reactions hepatotoxicity febrile neutropenia |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
C D33 antigen
|
| gptkbp:weight |
approximately 150 k Da
|